Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBCT vs BA vs Pharmacotherapy in MDD
NCT02624102Phase 3Completed
- Start
- Sep 2015
- Primary completion
- Dec 2017
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in major depressive disorder (MDD) (3 arms). Primary endpoint: Severity of Depression at 12 weeks. Started Sep 2015; status: completed.
02
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02624102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02624102.